4.7 Article

Lipid nanoparticles coated with chitosan using a one-step association method to target rifampicin to alveolar macrophages

Journal

CARBOHYDRATE POLYMERS
Volume 252, Issue -, Pages -

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.carbpol.2020.116978

Keywords

Alveolar epithelial cells; Association method; Chitosan; Infection; Mucoadhesion; Nanomedicine; Rifampicin

Funding

  1. FEDER trough COMPETE
  2. FCT, Fundacao para a Ciencia e Tecnologia [POCI-01-0145-FEDER-30624]
  3. CNPq Foundation, Ministry of Education of Brazil [153285/2018-4]
  4. FCT [CEECIND/01620/2017, DL 57/2016]
  5. FCT/MCTES
  6. [UID/QUI/50006/2019]
  7. Fundação para a Ciência e a Tecnologia [UID/QUI/50006/2019] Funding Source: FCT

Ask authors/readers for more resources

This study developed and characterized solid lipid nanoparticles loaded with rifampicin to enhance mucoadhesion and internalization by alveolar macrophages. The results showed promising drug entrapment efficiency and loading capacity, as well as effective mucoadhesive properties of the coated nanoparticles. These findings suggest that the developed system has potential to improve tuberculosis treatment.
This work proposes the development and characterization of solid lipid nanoparticles (SLNs) loaded with rifampicin (RIF) aiming to enhance mucoadhesion of the SLNs and consequently internalization by the alveolar macrophages (AMs). The lipid nanoparticles (NPs) were characterized and the results showed that the NPs obtained present a spherical or a starry shape with diameter around 250-500 nm, a monodisperse population, with zeta potential between-31 mV for uncoated SLNs and +33 mV for coated SLNs. The drug EE was approximately 90 % and the loading capacity (LC) 4.5 %. The SLNs coated with chitosan by the association method (aC-SLNs) show an effective mucoadhesive profile, verified by the turdimetry and surface loading method, corroborated with the cellular assays. The presence of chitosan in the aC-SLNs promotes higher mucoadhesive properties to the NPs and permeability in A549, suggesting that the safe aC-SLNs-RIF can be used as a promising drug delivery system for improving tuberculosis treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available